Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …

Background Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main
cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this …

Aims To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …

Abstract Background and Objective Rivaroxaban and apixaban are direct oral
anticoagulants increasing in popularity as convenient alternatives to warfarin. However …

Background Direct oral anticoagulants such as dabigatran are the preferred anticoagulant in
treating atrial fibrillation (AF) patients due to their effectiveness and safety. Whether this …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Background There are conflicting data on outcomes in patients with atrial fibrillation treated
with non–vitamin K oral anticoagulants across varying body mass index (BMI). We …

Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …